serum level of the hormone anti-mullerian as an anticipator of ovarian response to clomiphene citrate in females with polycystic ovarian syndrome

Background & objective: endocrine disorders like polycystic ovarian syndrome affect reproductive-age women. it causes infertility and has several clinical symptoms. clomiphene citrate ovulation induction is a first-line treatment. serum anti-mullerian hormone can indicate positive pregnancy outcomes in women with this disease, however this is controversial. to assess the value of anti-mullerian hormone (amh) as an anticipator of ovary response to clomiphene citrate in patients with “polycystic ovary syndrome (pcos). materials & methods: a cross-sectional study of 50 women diagnosed with rotterdam-based polycystic ovarian syndrome by two gynecologists was conducted. the maternity and pediatric teaching hospital in diwaniyah province, iraq, conducted the study from august 1, 2022, to may 15, 2023, at the obstetrics and gynecology department. women with diabetes or hypertension were excluded from the trial. these women sought medical treatment for infertility and received clomiphene citrate to induce ovulation. the findings of hcg urine and blood testing divided women into positive and negative biochemical pregnancy groups. results: the mean fsh of all recruited women was 5.19±1.14 iu/l, with no significant difference between pregnant and non-pregnant women (p = 0.849). amh levels were significantly lower in pregnant women compared to non-pregnant women (p< 0.001). the mean amh was 6.97±2.88 ng/ml for all enrolled women. roc curve research determined the optimal amh cutoff value for predicting positive biochemical pregnancy: ≤6.5 ng/ml with 100% sensitivity, 67.7% specificity, and 80.9 % accuracy. conclusion: serum anti-mullerian hormone accurately predicts pregnancy success in pcos women taking clomiphene citrate to induce ovulation.